Title
Category
Credits
Event date
Cost
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
  • Antipsychotics
  • Diagnostic Tools
  • Movement Disorders
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity, Dr Nierenberg describes the evaluation process. 
  • Adherence
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing nonadherence to antipsychotics.
  • Adherence
  • Antipsychotics
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this CME activity, learn how to use patient-centered care to enhance medication adherence and aid functional recovery in schizophrenia.
  • Adherence
  • Antipsychotics
  • Cognition
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.
  • Adherence
  • Antipsychotics
  • Cognition
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Learn more in this CME activity.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Finally, you can offer patients with tardive dyskinesia approved medications that reduce symptoms. In this CME, Dr Leslie Citrome reviews the evidence.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Tardive dyskinesia must be detected early to minimize the risk of permanence. Dr Stephen Saklad provides a refresher in this brief CME activity.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.

Pages